Literature DB >> 19617585

The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia.

John F Capacchione1, Sheila M Muldoon.   

Abstract

Exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia (MH) are complex syndromes with similar pathophysiology. All three are hypermetabolic states that include high demand for adenosine triphosphate, accelerated oxidative, chemical, and mechanical stress of muscle, and uncontrolled increase in intracellular calcium. Although there are no controlled clinical studies to support a relationship, there is evidence to suggest an association between unexpected heat/exercise intolerance and MH susceptibility. There are multiple case reports and a small number of clinical studies that have used in vitro muscle contracture testing and/or genetic testing to make the association. However, such methodology is problematic in that these tests are validated for clinical MH in association with anesthesia, and not for exertional heat illness or exertional rhabdomyolysis. Nevertheless, these relationships may have implications for some MH-susceptible patients and their capacity to exercise, as well as for clinicians treating and anesthetizing patients with histories of unexplained exertional heat and exercise illnesses.

Entities:  

Mesh:

Year:  2009        PMID: 19617585     DOI: 10.1213/ane.0b013e3181a9d8d9

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  37 in total

Review 1.  Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure.

Authors:  Olivier Boutaud; L Jackson Roberts
Journal:  Free Radic Biol Med       Date:  2010-10-27       Impact factor: 7.376

2.  Delayed-onset rhabdomyolysis after intense exercise.

Authors:  Mathew Kiberd; Sam Campbell
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262

Review 3.  Ryanodine receptors: structure and function.

Authors:  Filip Van Petegem
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 4.  Special article: Future directions in malignant hyperthermia research and patient care.

Authors:  Sharon J Hirshey Dirksen; Marilyn Green Larach; Henry Rosenberg; Barbara W Brandom; Jerome Parness; Robert Scott Lang; Meera Gangadharan; Tyler Pezalski
Journal:  Anesth Analg       Date:  2011-06-27       Impact factor: 5.108

5.  Rhabdomyolysis. The role of diagnostic and prognostic factors.

Authors:  Eran Keltz; Fahmi Yousef Khan; Gideon Mann
Journal:  Muscles Ligaments Tendons J       Date:  2014-02-24

6.  Oxidative capacity and fatigability in run-trained malignant hyperthermia-susceptible mice.

Authors:  Clement Rouviere; Benjamin T Corona; Christopher P Ingalls
Journal:  Muscle Nerve       Date:  2012-04       Impact factor: 3.217

7.  Effect of prior exercise on thermal sensitivity of malignant hyperthermia-susceptible muscle.

Authors:  Benjamin T Corona; Susan L Hamilton; Christopher P Ingalls
Journal:  Muscle Nerve       Date:  2010-08       Impact factor: 3.217

8.  Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.

Authors:  Sheila Riazi; Natalia Kraeva; Sheila M Muldoon; James Dowling; Clara Ho; Maria-Alexandra Petre; Jerome Parness; Robert T Dirksen; Henry Rosenberg
Journal:  Can J Anaesth       Date:  2014-09-05       Impact factor: 5.063

Review 9.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

10.  Therapeutic plasma exchange in the treatment of exertional heat stroke and multiorgan failure.

Authors:  Vimal Master Sankar Raj; Amanda Alladin; Brent Pfeiffer; Chryso Katsoufis; Marissa Defreitas; Alicia Edwards-Richards; Jayanthi Chandar; Wacharee Seeherunvong; Gwenn McLaughlin; Gaston Zilleruelo; Carolyn L Abitbol
Journal:  Pediatr Nephrol       Date:  2013-01-22       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.